Insights

Peter Voorhees, MD and Louis Williams, MD discuss how CAR T-cell therapy eligibility assessment, optimal timing for earlier-line treatment, long-term efficacy data from CARTITUDE studies, and emerging next-generation CAR T products are reshaping the treatment landscape for relapsed/refractory multiple myeloma patients.

Julia Foldi, MD, PhD; Elisa Krill-Jackson, MD; and Timothy J. Pluard, MD, discuss how the INAVO120 trial’s final overall survival (OS) analysis demonstrates a significant 7-month median OS benefit (34 vs 27 months) with inavolisib plus palbociclib plus fulvestrant in PIK3CA-mutated endocrine-resistant metastatic breast cancer, though the limited crossover rate (< 10%) to PIK3CA inhibitors in the control arm complicates interpretation of optimal sequencing strategies.

Paul E. Oberstein, MD; Priyadarshini Pathak, MBBS; and Tara E. Seery, MD, discuss how to optimize treatment decisions for patients with pancreatic cancer by comparing NALIRIFOX vs modified FOLFIRINOX regimens, sequencing therapies from first to second line, managing toxicities through dose modifications to maintain patients on treatment longer, and the promising pipeline of emerging targeted therapies including KRAS inhibitors and immunotherapy combinations presented at ASCO 2025.

Sandip P. Patel, MD; Zofia Piotrowska, MD, MHS; and Joel Neal, MD, PhD, discuss how the evolving landscape of EGFR-mutated non–small cell lung cancer treatment now includes 3 compelling frontline options (osimertinib monotherapy, FLAURA2 regimen, and MARIPOSA), requiring careful consideration of patient factors, disease characteristics, and toxicity profiles for optimal treatment selection and sequencing strategies.

Panelists discuss RAS mutations in pancreatic cancer, focusing on prevalence and testing, evolving second-line treatment strategies including emerging targeted agents like daraxonrasib, and key ASCO 2025 highlights and future perspectives in pancreatic ductal adenocarcinoma (PDAC).

Jason A. Mouabbi, MD, discusses how ESR1 mutations should be monitored after each progression in hormone receptor-positive breast cancer patients and treated with elacestrant, emphasizing the importance of liquid biopsies for detection and the promising results from studies like SERENA-6 that suggest switching therapy early based on molecular progression rather than waiting for radiological evidence.

Joshua Sabari, MD and Isabel Preeshagul, DO, MBS, discuss how comprehensive biomarker testing for HER2 mutations in non–small cell lung cancer (NSCLC) enables targeted treatment with emerging therapies including antibody-drug conjugates such as trastuzumab deruxtecan and promising oral tyrosine kinase inhibitors such as zongertinib and sevabertinib, which offer improved tolerability and central nervous system penetration compared with traditional chemotherapy approaches.

Panelists discuss how comprehensive biomarker testing informs patient selection for antibody-drug conjugate (ADC) therapy in HER2+ ovarian and endometrial cancers, while evaluating ADC positioning in the evolving gynecologic oncology landscape, comparing structural components that influence efficacy and safety, and outlining strategies for monitoring and managing emerging ADC toxicities.

Catherine Coombs; John Allan, MD, and Joanna Rhodes, MD, MSCE, discuss how to manage chronic lymphocytic leukemia (CLL) patients who develop high-risk disease features at relapse after initial venetoclax-based therapy, covering treatment sequencing strategies, BTK inhibitor tolerability issues and switching approaches, retreatment considerations, and emerging therapies including CAR-T cell therapy and novel agents in development.

Panelists discuss the expanding treatment landscape for neuroendocrine tumors.

Panelists discuss the treatment of relapsed and refractory multiple myeloma, as well as sequencing strategies aimed at optimizing patient care and minimizing treatment-related side effects,presenting two real-world patient cases and explain our treatment approach, highlighting how they incorporate recent data into our practice.

Kelly E. McCann, MD, PhD; and Gregory Vidal, MD, PhD, discuss how triple-positive breast cancer (hormone receptor positive and HER2 positive) requires specialized treatment approaches, including standard taxane with pertuzumab-trastuzumab combinations, the integration of CDK 4/6 inhibitors, considerations for ovarian suppression in premenopausal patients, and sequential therapy options for metastatic disease including antibody-drug conjugates and tyrosine kinase inhibitors.

Panelists discuss how immune-oncology therapies and biomarkers like TMB, MSI, and HER2 are shaping treatment strategies and decision-making in advanced endometrial cancer, highlighting the need for further research and improved sequencing approaches.

Experts discuss the latest clinical data on tyrosine kinase inhibitor (TKI) therapy for gastrointestinal stromal tumors (GIST), focusing on optimizing treatment selection and sequencing strategies for patients progressing beyond first-line therapy, with insights into how molecular characterization and recent clinical trials inform decisions across multiple treatment lines, illustrated through patient case discussions.